Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure.

Eugene Morkin; Gregory Pennock; Peter H. Spooner; Joseph J. Bahl; Katherine Underhill Fox; Steven Goldman

doi:10.1159/000063110

Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure.

Eugene Morkin, Gregory Pennock, Peter H. Spooner, Joseph J. Bahl, Katherine Underhill Fox, Steven Goldman

Medicine

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

After an initial safety study in 7 normal volunteers, a randomized double-blind comparison was made between 3,5-diiodothyropropionic acid (DITPA) and placebo in 19 patients with moderately severe congestive failure. In heart failure patients receiving the drug for 4 weeks, cardiac index was increased (p = 0.04) and systemic vascular resistance index was decreased (p = 0.02). Systolic cardiac function was unchanged but isovolumetric relaxation time was decreased significantly, suggesting improvement in diastolic function. Total serum cholesterol (p = 0.005) and triglycerides (p = 0.01) also were decreased significantly. DITPA could represent a useful new agent for treatment of congestive heart failure.

Original language	English (US)
Pages (from-to)	218-225
Number of pages	8
Journal	Cardiology
Volume	97
Issue number	4
DOIs	https://doi.org/10.1159/000063110
State	Published - 2002

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Access to Document

10.1159/000063110

Cite this

@article{e06894589559473a916f5eec1a4b6ad7,

title = "Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure.",

abstract = "After an initial safety study in 7 normal volunteers, a randomized double-blind comparison was made between 3,5-diiodothyropropionic acid (DITPA) and placebo in 19 patients with moderately severe congestive failure. In heart failure patients receiving the drug for 4 weeks, cardiac index was increased (p = 0.04) and systemic vascular resistance index was decreased (p = 0.02). Systolic cardiac function was unchanged but isovolumetric relaxation time was decreased significantly, suggesting improvement in diastolic function. Total serum cholesterol (p = 0.005) and triglycerides (p = 0.01) also were decreased significantly. DITPA could represent a useful new agent for treatment of congestive heart failure.",

author = "Eugene Morkin and Gregory Pennock and Spooner, {Peter H.} and Bahl, {Joseph J.} and {Underhill Fox}, Katherine and Steven Goldman",

year = "2002",

doi = "10.1159/000063110",

language = "English (US)",

volume = "97",

pages = "218--225",

journal = "Cardiology",

issn = "0008-6312",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure.

AU - Morkin, Eugene

AU - Pennock, Gregory

AU - Spooner, Peter H.

AU - Bahl, Joseph J.

AU - Underhill Fox, Katherine

AU - Goldman, Steven

PY - 2002

Y1 - 2002

N2 - After an initial safety study in 7 normal volunteers, a randomized double-blind comparison was made between 3,5-diiodothyropropionic acid (DITPA) and placebo in 19 patients with moderately severe congestive failure. In heart failure patients receiving the drug for 4 weeks, cardiac index was increased (p = 0.04) and systemic vascular resistance index was decreased (p = 0.02). Systolic cardiac function was unchanged but isovolumetric relaxation time was decreased significantly, suggesting improvement in diastolic function. Total serum cholesterol (p = 0.005) and triglycerides (p = 0.01) also were decreased significantly. DITPA could represent a useful new agent for treatment of congestive heart failure.

AB - After an initial safety study in 7 normal volunteers, a randomized double-blind comparison was made between 3,5-diiodothyropropionic acid (DITPA) and placebo in 19 patients with moderately severe congestive failure. In heart failure patients receiving the drug for 4 weeks, cardiac index was increased (p = 0.04) and systemic vascular resistance index was decreased (p = 0.02). Systolic cardiac function was unchanged but isovolumetric relaxation time was decreased significantly, suggesting improvement in diastolic function. Total serum cholesterol (p = 0.005) and triglycerides (p = 0.01) also were decreased significantly. DITPA could represent a useful new agent for treatment of congestive heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0036043679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036043679&partnerID=8YFLogxK

U2 - 10.1159/000063110

DO - 10.1159/000063110

M3 - Article

C2 - 12145478

AN - SCOPUS:0036043679

SN - 0008-6312

VL - 97

SP - 218

EP - 225

JO - Cardiology

JF - Cardiology

IS - 4

ER -

Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this